Drug Profile
Anti-CAIX monoclonal antibody - Checkpoint Therapeutics/Dana-Farber Cancer Institute
Alternative Names: Anti-CAIX antibody; Anti-carbonic anhydrase IX antibody; Anti-carbonic anhydrase IX monoclonal antibodyLatest Information Update: 08 Apr 2022
Price :
$50
*
At a glance
- Originator Dana-Farber Cancer Institute
- Developer Checkpoint Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Renal cell carcinoma